Sponsor or institution
Clinical trials and research at iCell Gene Therapeutics
As of November 12, 2026, Find a Trial lists 5 clinical trials run by iCell Gene Therapeutics that are recruiting, at sites in 2 countries (most in China (4), United States (1)). By phase: Phase 1 (4), Phase 2 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 5Clinical trials
- 2Countries
Newest trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| BCMA-CD19 cCAR-T cell therapy for refractory inflammatory myopathy | Phase 1 | Chengdu, Sichuan | Recruiting | Jul 20, 2026 |
| CAR-T cells targeting CD33 and CLL1 for relapsed or refractory AML | Phase 1 | Nanchang, Jiangxi and 1 other locations | Recruiting | Jun 25, 2026 |
| A CAR-T therapy for hard-to-treat systemic lupus with or without lupus nephritis | Phase 2 | Chicago, Illinois and 3 other locations | Recruiting | Jan 9, 2026 |
| Treatment for Immune Thrombocytopenia Using CAR T Cells | Phase 1 | Chengdu, Sichuan | Recruiting | Jan 22, 2025 |
| Dual-target BCMA–CD19 CAR T-cell therapy for relapsed or refractory multiple myeloma and plasmacytoid lymphoma | Phase 1 | Shenzhen, Guangdong and 1 other locations | Recruiting | Nov 14, 2019 |
All recruiting trials (5)
-
BCMA-CD19 cCAR-T cell therapy for refractory inflammatory myopathy
This trial tests a special CAR-T cell therapy (ICG318) in adults with refractory inflammatory myopathy to see if it is safe and tolerable.
-
CAR-T cells targeting CD33 and CLL1 for relapsed or refractory AML
A one-arm early-stage trial tests whether a patient’s own engineered CAR-T cells (ICG415) can be safely given after conditioning chemotherapy to see if they can help adults with relapsed or refractory AML.
-
A CAR-T therapy for hard-to-treat systemic lupus with or without lupus nephritis
This phase 2a study tests a single infusion of ICG318 CAR-T cells in adults and eligible teens with refractory SLE, with or without lupus nephritis.
-
Treatment for Immune Thrombocytopenia Using CAR T Cells
This study is testing a new CAR T cell therapy to see if it can help people with hard-to-treat immune thrombocytopenia by targeting the cells causing their condition.
-
Dual-target BCMA–CD19 CAR T-cell therapy for relapsed or refractory multiple myeloma and plasmacytoid lymphoma
This treatment will try a dual-target CAR T-cell therapy that attacks BCMA and CD19 in people with relapsed or refractory multiple myeloma or plasmacytoid lymphoma who have exhausted standard options.
Quick answers
How many clinical trials run by iCell Gene Therapeutics are recruiting right now?
5, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 2 countries. The most sites are in China (4 trials), United States (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 1: 4, Phase 2: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.